MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 4,176 Shares of Insmed, Inc. $INSM

Key Points

• MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Insmed, Inc. by 4.0%, owning approximately 0.06% of the company, valued at $8,364,000 after purchasing an additional 4,176 shares in the first quarter.
• In the same quarter, multiple institutional investors significantly raised their stakes in Insmed, including Cullen Frost Bankers with a 164.9% increase, and Versant Capital Management with a 546.3% increase.
• Insmed's revenue for the last quarter was $107.42 million, beating estimates, although it reported a loss of ($1.70) earnings per share, missing analysts' expectations of ($1.30).

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 4.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 109,489 shares of the biopharmaceutical company's stock after acquiring an additional 4,176 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. owned approximately 0.06% of Insmed worth $8,364,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. boosted its position in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 221 shares during the period. Elequin Capital LP purchased a new stake in Insmed during the 4th quarter worth $28,000. NBC Securities Inc. purchased a new stake in Insmed during the 1st quarter worth $49,000. Versant Capital Management Inc boosted its position in Insmed by 546.3% during the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock worth $53,000 after purchasing an additional 590 shares during the period. Finally, Signaturefd LLC boosted its position in Insmed by 60.0% during the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock worth $66,000 after purchasing an additional 325 shares during the period.

Insider Transactions at Insmed

In other Insmed news, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $129.50, for a total value of $1,295,000.00. Following the completion of the sale, the director owned 274,516 shares in the company, valued at $35,549,822. This represents a 3.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Roger Adsett sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total transaction of $3,189,500.00. Following the completion of the sale, the chief operating officer owned 105,637 shares of the company's stock, valued at approximately $13,477,168.46. The trade was a 19.14% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 378,382 shares of company stock worth $40,169,038. 3.00% of the stock is currently owned by insiders.

Insmed Price Performance

NASDAQ:INSM traded up $0.14 during trading hours on Friday, reaching $145.93. 1,926,423 shares of the company's stock were exchanged, compared to its average volume of 2,206,758. The company has a market capitalization of $30.85 billion, a P/E ratio of -25.56 and a beta of 0.97. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $149.08. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The business's 50-day simple moving average is $119.40 and its two-hundred day simple moving average is $91.91.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same period in the prior year, the business posted ($1.94) EPS. The company's revenue for the quarter was up 18.9% on a year-over-year basis. Insmed has set its FY 2025 guidance at EPS. Sell-side analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on INSM shares. Mizuho upped their price objective on shares of Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a research report on Wednesday, August 13th. Leerink Partners increased their price target on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 10th. Jefferies Financial Group increased their price target on shares of Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. Royal Bank Of Canada increased their price target on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Finally, Bank of America increased their price target on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research report on Wednesday, June 11th. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $139.86.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.